Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025
Portfolio Pulse from
Adaptive Biotechnologies announced that the Medicare Clinical Laboratory Fee Schedule rate for its clonoSEQ test is set at $2,007, effective January 1, 2025.
January 07, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies' clonoSEQ test has been assigned a Medicare fee schedule rate of $2,007, effective January 1, 2025. This could positively impact the company's revenue from this test.
The establishment of a Medicare fee schedule rate for the clonoSEQ test at $2,007 is likely to enhance revenue predictability and potentially increase sales, as it provides a clear reimbursement framework for healthcare providers. This is a positive development for Adaptive Biotechnologies, as it may lead to increased adoption of the test.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100